Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101355 | 0.86 | MTNR1A (0.44) | MTNR1AMTNR1BMAPTSMN1; SMN2KDM4E | |
| SCHEMBL16627089 | 0.85 | MTNR1A (0.45) | MTNR1AMTNR1BNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL16624688 | 0.83 | ALDH1A1 (0.50) | MTNR1AMTNR1BNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17955289 | 0.83 | MTNR1A (0.42) | MTNR1AMTNR1BMAPTSMN1; SMN2KDM4E | |
| SCHEMBL17955301 | 0.82 | MTNR1A (0.41) | MTNR1AMTNR1BMAPTSMN1; SMN2TP53 | |
| SCHEMBL16627109 | 0.82 | CYP1A2 (0.47) | MTNR1AMTNR1BNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17954338 | 0.82 | ALDH1A1 (0.49) | MTNR1AMTNR1BNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17955298 | 0.82 | MTNR1A (0.42) | MTNR1AMTNR1BMAPTSMN1; SMN2KDM4E | |
| SCHEMBL16624680 | 0.81 | ALDH1A1 (0.53) | MTNR1AMTNR1BNPSR1MAPTSMN1; SMN2 | |
| SCHEMBL17954340 | 0.79 | NR1H2 (0.49) | MTNR1AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | MTNR1A 4138/4885MTNR1B 4314/4885NPSR1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.